eISSN: 2084-9885
ISSN: 1896-6764
Neuropsychiatria i Neuropsychologia/Neuropsychiatry and Neuropsychology
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
3/2012
vol. 7
 
Share:
Share:
more
 
 
abstract:

Review article
Procognitive strategies in the augmentation of antipsychotic therapy in schizophrenia

Justyna Holka-Pokorska

Neuropsychiatria i Neuropsychologia 2012; 7, 3: 130–138
Online publish date: 2012/11/20
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Modern antipsychotic drugs with the antidopaminergic mechanism supplemented with a serotonergic mechanism are not sufficiently effective against negative and cognitive symptoms of schizophrenia. However, effective pharmacotherapeutic or rehabilitation strategies for these symptoms in the course of schizophrenia have not yet been developed. The aim of the present work is to discuss the theoretical, experimental and clinical trials on the use of combined therapy in schizophrenia based on interventions that can provide cognitive effects.

One of the directions of pharmacotherapy of schizophrenia could become “rational polypharmacy” aimed at improving cognitive functioning. In this regard there are numerous studies of procognitive drugs based on NMDA glutamate receptors, nicotinic cholinergic receptors or dopamine D1 receptors. Clinical effects of these groups of substances so far have not proved satisfactory. On the other hand, extensive research in this direction is being undertaken on agonists or positive modulators of mGlu receptors of groups 2/3 and 5. These substances in preclinical studies proved to be effective against cognitive symptoms of schizophrenia.

In some recent studies, substances with glutamatergic action proved to deliver improvement in fighting both positive and negative symptoms of schizophrenia. However, the procognitive effects of these substances have been demonstrated only in experimental research.
keywords:

procognitive drugs, schizophrenia, glutamatergic hypothesis

Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe